trial

Early Medication Discontinuation and Long-term Clinical Outcome in FEP

NCTId NCT01926340
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 178 (actual)
Sponsored by Professor Eric Y.H. Chen
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
178 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2013-11
Primary completion
2014-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
—

Sponsors

Professor Eric Y.H. ChenLead Sponsor
Research Grants Council, Hong KongCollaborator
AstraZenecaCollaborator
Food and Health Bureau, Hong KongCollaborator
University of British ColumbiaCollaborator

Investigators

1
Eric Yu Hai Chen, MDPrincipal Investigator

Sites

1 total
Hong Kong, Hong Kong

Facts & assertions

4 sourced
Enrollment
178
Phase
NA
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
Professor Eric Y.H. Chen
company
collaborator
Research Grants Council, Hong Kong
company
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Eric Yu Hai Chen, MD
person